Top Story

Targeted fusion-guided biopsy improved detection of high-risk prostate cancers

January 27, 2015

Targeted magnetic resonance/ultrasound fusion prostate biopsy detected significantly more cases of high-risk prostate cancers than standard extended-sextant biopsy in men undergoing biopsy for suspected prostate cancer, according to study results.

“This study demonstrates that targeted fusion-guided biopsy could significantly enhance our ability to identify patients with high-risk prostate cancers that need more aggressive treatment,” researcher Mohummad Minhaj Siddiqui, MD, assistant professor of surgery at the University of Maryland School of Medicine and director of urologic robotic surgery at the University of Maryland Marlene and Stewart Greenebaum Cancer Center, said in a press release. “With fusion technology, we now have a tool to help us differentiate high-risk cancers from low-risk ones that may require minimal or no treatment. There is a concern that we over-diagnose and over-treat low-risk cancers that are unlikely to be terminal, and this technology enables us to make a more reliable diagnosis than the current standard practice.”

Meeting News Coverage

Pembrolizumab appears safe, effective in advanced gastric cancer

January 27, 2015
The novel agent pembrolizumab demonstrated promising antitumor activity and manageable toxicity in patients with advanced gastric cancer, according to study results…
Kim F. Rhoads, MD In the Journals

Integrated health care may eliminate racial disparities in colon cancer survival

January 26, 2015
Providing fair, high-quality, evidence-based care can eliminate racial disparities in survival outcomes among patients with colon cancer, according to results of a…
Breaking News

FDA approves Triferic for iron replacement in patients with chronic kidney disease

January 26, 2015
The FDA today approved Triferic to treat iron loss in patients with chronic kidney disease who are on dialysis, according to the drug’s manufacturer.Triferic…
Mikkael A. Sekeres In the Journals

Azacitidine, lenalidomide treatment appears safe for myelodysplastic syndrome, AML

January 26, 2015
A sequential treatment combination of lenalidomide and azacitidine appeared active in and safe for patients with high-risk myelodysplastic syndrome or acute myeloid…
More News Headlines »
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »